Skip to main content
Top
Published in: Diabetologia 10/2004

01-10-2004 | Article

A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)

Authors: P. M. Clarke, A. M. Gray, A. Briggs, A. J. Farmer, P. Fenn, R. J. Stevens, D. R. Matthews, I. M. Stratton, R. R. Holman, on behalf of the UK Prospective Diabetes Study (UKPDS) Group

Published in: Diabetologia | Issue 10/2004

Login to get access

Abstract

Aims/hypothesis

The aim of this study was to develop a simulation model for Type 2 diabetes that can be used to estimate the likely occurrence of major diabetes-related complications over a lifetime, in order to calculate health economic outcomes such as quality-adjusted life expectancy.

Methods

Equations for forecasting the occurrence of seven diabetes-related complications and death were estimated using data on 3642 patients from the United Kingdom Prospective Diabetes Study (UKPDS). After examining the internal validity, the UKPDS Outcomes Model was used to simulate the mean difference in expected quality-adjusted life years between the UKPDS regimens of intensive and conventional blood glucose control.

Results

The model’s forecasts fell within the 95% confidence interval for the occurrence of observed events during the UKPDS follow-up period. When the model was used to simulate event history over patients’ lifetimes, those treated with a regimen of conventional glucose control could expect 16.35 undiscounted quality-adjusted life years, and those receiving treatment with intensive glucose control could expect 16.62 quality-adjusted life years, a difference of 0.27 (95% CI: −0.48 to 1.03).

Conclusions/interpretations

The UKPDS Outcomes Model is able to simulate event histories that closely match observed outcomes in the UKPDS and that can be extrapolated over patients’ lifetimes. Its validity in estimating outcomes in other groups of patients, however, remains to be evaluated. The model allows simulation of a range of long-term outcomes, which should assist in informing future economic evaluations of interventions in Type 2 diabetes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Eastman RC, Javitt JC, Herman WH et al. (1997) Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 20:725–734PubMed Eastman RC, Javitt JC, Herman WH et al. (1997) Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 20:725–734PubMed
2.
go back to reference Brown JB, Russell A, Chan W, Pedula K, Aickin M (2000) The global diabetes model: user friendly version 3.0. Diabetes Res Clin Pract 50 [Suppl 3]:S15–S46 Brown JB, Russell A, Chan W, Pedula K, Aickin M (2000) The global diabetes model: user friendly version 3.0. Diabetes Res Clin Pract 50 [Suppl 3]:S15–S46
3.
go back to reference Palmer AJ, Brandt A, Valerio G, Weiss C, Stock H, Wenzel H (2000) Outline of a diabetes disease management model. Principles and applications. Diabetes Res Clin Pract 50 [Suppl 3]:S47–S56 Palmer AJ, Brandt A, Valerio G, Weiss C, Stock H, Wenzel H (2000) Outline of a diabetes disease management model. Principles and applications. Diabetes Res Clin Pract 50 [Suppl 3]:S47–S56
4.
go back to reference Bagust A, Hopkinson PK, Maier W, Currie CJ (2001) An economic model of the long-term health care burden of Type II diabetes. Diabetologia 44:2140–2155CrossRefPubMed Bagust A, Hopkinson PK, Maier W, Currie CJ (2001) An economic model of the long-term health care burden of Type II diabetes. Diabetologia 44:2140–2155CrossRefPubMed
5.
go back to reference CDC Group (2002) Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287:2542–2551PubMed CDC Group (2002) Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287:2542–2551PubMed
6.
go back to reference DCCT (1996) Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. JAMA 276:1409–1415PubMed DCCT (1996) Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. JAMA 276:1409–1415PubMed
7.
go back to reference Yeo WW, Yeo KR (2001) Predicting CHD risk in patients with diabetes mellitus. Diabet Med 18:341–344CrossRefPubMed Yeo WW, Yeo KR (2001) Predicting CHD risk in patients with diabetes mellitus. Diabet Med 18:341–344CrossRefPubMed
8.
go back to reference UKPDS Group (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412CrossRefPubMed UKPDS Group (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412CrossRefPubMed
9.
go back to reference Adler AI, Stratton IM, Neil HA et al. (2000) Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321:412–419CrossRefPubMed Adler AI, Stratton IM, Neil HA et al. (2000) Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321:412–419CrossRefPubMed
10.
go back to reference Stevens RJ, Kothari V, Adler AI, Stratton IM (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 101:671–679CrossRef Stevens RJ, Kothari V, Adler AI, Stratton IM (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 101:671–679CrossRef
11.
go back to reference Kothari V, Stevens RJ, Adler AI et al. (2002) UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 33:1776–1781CrossRefPubMed Kothari V, Stevens RJ, Adler AI et al. (2002) UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 33:1776–1781CrossRefPubMed
12.
go back to reference UKPDS Group (1991) UK Prospective Diabetes Study VIII: study design, progress and performance. Diabetologia 34:877–890PubMed UKPDS Group (1991) UK Prospective Diabetes Study VIII: study design, progress and performance. Diabetologia 34:877–890PubMed
13.
go back to reference UKPDS Group (1994) Biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med 11:534–544PubMed UKPDS Group (1994) Biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med 11:534–544PubMed
14.
go back to reference Hougaard P (2000) Analysis of multivariate survival data (Statistics for biology and health). Springer, Berlin Hougaard P (2000) Analysis of multivariate survival data (Statistics for biology and health). Springer, Berlin
15.
go back to reference American Diabetes Association (1998) Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 21:296–309PubMed American Diabetes Association (1998) Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 21:296–309PubMed
16.
go back to reference Brown JB, Pedula KL, Bakst AW (1999) The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med 159:1873–1880CrossRefPubMed Brown JB, Pedula KL, Bakst AW (1999) The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med 159:1873–1880CrossRefPubMed
17.
go back to reference Wolf PA, D’Agostino RB, Belanger AJ, Kannel WB (1991) Probability of stroke: a risk profile from the Framingham Study. Stroke 22:312–318PubMed Wolf PA, D’Agostino RB, Belanger AJ, Kannel WB (1991) Probability of stroke: a risk profile from the Framingham Study. Stroke 22:312–318PubMed
18.
go back to reference Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Davignon DR, Smith DG (1999) A prospective study of risk factors for diabetic foot ulcer. The Seattle Diabetic Foot Study. Diabetes Care 22:1036–1042PubMed Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Davignon DR, Smith DG (1999) A prospective study of risk factors for diabetic foot ulcer. The Seattle Diabetic Foot Study. Diabetes Care 22:1036–1042PubMed
19.
go back to reference Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ (1997) Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA 278:2069–2074CrossRefPubMed Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ (1997) Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA 278:2069–2074CrossRefPubMed
20.
go back to reference UKPDS Group (2003) Development and progression of nephropathy in Type 2 diabetes: observation and modelling from the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63:225–232CrossRefPubMed UKPDS Group (2003) Development and progression of nephropathy in Type 2 diabetes: observation and modelling from the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63:225–232CrossRefPubMed
21.
go back to reference Cupples LA, D’Agostino RB, Anderson K, Kannel WB (1988) Comparison of baseline and repeated measure covariate techniques in the Framingham Heart Study. Stat Med 7:205–222PubMed Cupples LA, D’Agostino RB, Anderson K, Kannel WB (1988) Comparison of baseline and repeated measure covariate techniques in the Framingham Heart Study. Stat Med 7:205–222PubMed
22.
go back to reference Altman DG, De Stavola BL (1994) Practical problems in fitting a proportional hazards model to data with updated measurements of the covariates. Stat Med 13:301–341PubMed Altman DG, De Stavola BL (1994) Practical problems in fitting a proportional hazards model to data with updated measurements of the covariates. Stat Med 13:301–341PubMed
23.
go back to reference Greene WH (1997) Econometric analysis, 4 edn. Prentice-Hall, London Greene WH (1997) Econometric analysis, 4 edn. Prentice-Hall, London
24.
go back to reference UKPDS Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRefPubMed UKPDS Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRefPubMed
25.
go back to reference Panzram G (1987) Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 30:123–131PubMed Panzram G (1987) Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 30:123–131PubMed
26.
go back to reference Wright JC, Weinstein MC (1998) Gains in life expectancy from medical interventions—standardizing data on outcomes. N Engl J Med 339:380–386CrossRefPubMed Wright JC, Weinstein MC (1998) Gains in life expectancy from medical interventions—standardizing data on outcomes. N Engl J Med 339:380–386CrossRefPubMed
27.
go back to reference EuroQol Group (1990) EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16:199–208CrossRefPubMed EuroQol Group (1990) EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16:199–208CrossRefPubMed
28.
go back to reference Clarke P, Gray A, Holman R (2002) Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 22:340–349CrossRefPubMed Clarke P, Gray A, Holman R (2002) Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 22:340–349CrossRefPubMed
29.
go back to reference Altman DG, Royston P (2000) What do we mean by validating a prognostic model? Stat Med 19:453–473CrossRefPubMed Altman DG, Royston P (2000) What do we mean by validating a prognostic model? Stat Med 19:453–473CrossRefPubMed
30.
go back to reference Gray A, Raikou M, McGuire A et al. (2000) Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ 320:1373–1378CrossRefPubMed Gray A, Raikou M, McGuire A et al. (2000) Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ 320:1373–1378CrossRefPubMed
32.
go back to reference Government Actuary’s Department (2003) Interim life tables 1999–2001. The Stationery Office, London Government Actuary’s Department (2003) Interim life tables 1999–2001. The Stationery Office, London
33.
go back to reference Williams R, Van Gaal L, Lucioni C (2002) Assessing the impact of complications on the costs of Type II diabetes. Diabetologia 45:S13–S17CrossRefPubMed Williams R, Van Gaal L, Lucioni C (2002) Assessing the impact of complications on the costs of Type II diabetes. Diabetologia 45:S13–S17CrossRefPubMed
34.
go back to reference Anderson KM, Odell PM, Wilson PW, Kannel WB (1991) Cardiovascular disease risk profiles. Am Heart J 121:293–298CrossRefPubMed Anderson KM, Odell PM, Wilson PW, Kannel WB (1991) Cardiovascular disease risk profiles. Am Heart J 121:293–298CrossRefPubMed
35.
go back to reference Menotti A, Lanti M, Puddu PE (2000) Long-term time-related predictivity of coronary events as a function of a single measurement of serum cholesterol and systolic blood pressure. Acta Cardiol 55:87–93PubMed Menotti A, Lanti M, Puddu PE (2000) Long-term time-related predictivity of coronary events as a function of a single measurement of serum cholesterol and systolic blood pressure. Acta Cardiol 55:87–93PubMed
36.
go back to reference Stevens R, Adler A, Gray A, Briggs A, Holman R (2000) Life-expectancy projection by modelling and computer simulation (UKPDS 46). Diabetes Res Clin Pract 50 [Suppl 3]:S5–S13 Stevens R, Adler A, Gray A, Briggs A, Holman R (2000) Life-expectancy projection by modelling and computer simulation (UKPDS 46). Diabetes Res Clin Pract 50 [Suppl 3]:S5–S13
Metadata
Title
A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)
Authors
P. M. Clarke
A. M. Gray
A. Briggs
A. J. Farmer
P. Fenn
R. J. Stevens
D. R. Matthews
I. M. Stratton
R. R. Holman
on behalf of the UK Prospective Diabetes Study (UKPDS) Group
Publication date
01-10-2004
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2004
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1527-z

Other articles of this Issue 10/2004

Diabetologia 10/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.